A Patient with Corneal Epithelial Disorder That Developed after Administration of a Latanoprost Generic, but Not a Brand-Name Drug, Eye Drop
Background. We report a patient who developed corneal epithelial disorder repeatedly after changing the prescription from Xalatan eye drops (Pfizer Inc.) to Latanoprost eye drops (Kaken Pharmaceutical Co., Ltd.), both containing 0.005% latanoprost. Case Report. An 88-year-old male with glaucoma had...
Saved in:
Main Authors: | Yukihisa Takada, Yuka Okada, Norihito Fujita, Shizuya Saika |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Case Reports in Ophthalmological Medicine |
Online Access: | http://dx.doi.org/10.1155/2012/536746 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Latanoprost Induced Iris Pigment Epithelial and Ciliary Body Cyst Formation in Hypermetropic Eyes
by: Abhijit Anand Mohite, et al.
Published: (2017-01-01) -
Development and Validation of a Precise Method for Determination of Benzalkonium Chloride (BKC) Preservative, in Pharmaceutical Formulation of Latanoprost Eye Drops
by: J. Mehta, et al.
Published: (2010-01-01) -
Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
by: L. Tang, et al.
Published: (2018-01-01) -
On Some Unrecorded Generic and Specific Names
by: A. N. Caudell
Published: (1907-01-01) -
Some Corrections in Generic Names in Orthoptera
by: Jerome McNeill
Published: (1897-01-01)